COVID wave looms in Europe as booster campaign makes slow start
and Natalie Grover
Oct 6 (Reuters) – A new COVID-19 wave appears to be brewing in Europe as cooler weather arrives, with public health experts warning that vaccine fatigue and confusion over types of available vaccines will likely limit booster uptake.
Omicron subvariants BA.4/5 that dominated this summer are still behind the majority of infections, but newer Omicron subvariants are gaining ground. Hundreds of new forms of Omicron are being tracked by scientists, World Health Organisation (WHO) officials said this week.
WHO data released late on Wednesday showed that cases in the European Union (EU) reached 1.5 million last week, up 8% from the prior week, despite a dramatic fall in testing. Globally, case numbers continue to decline.
Hospitalisation numbers across many countries in the 27-nation bloc, as well as Britain, have gone up in recent weeks.
In the week ended Oct 4, COVID-19 hospital admissions with symptoms jumped nearly 32% in Italy, while intensive care admissions rose about 21%, compared to the week before, according to data compiled by independent scientific foundation Gimbe.
Over the same week, COVID hospitalisations in Britain saw a 45% increase versus the week earlier.
Omicron-adapted vaccines have launched in Europe as of September, with two types of shots addressing the BA.1 as well as the BA.4/5 subvariants made available alongside existing first-generation vaccines. In Britain, only the BA.1-tailored shots have been given the green light.
European and British officials have endorsed the latest boosters only for a select groups of people, including the elderly and those with compromised immune systems. Complicating matters further is the “choice” of vaccine as a booster, which will likely add to confusion, public health experts said.
But willingness to get yet another shot, which could be a fourth or fifth for some, is wearing thin.
“For those who may be less concerned about their risk, the messaging that it is all over coupled with the lack of any major publicity campaign is likely to reduce uptake,” said Martin McKee, professor of European public health at the London School of Hygiene and Tropical Medicine.
FALSE SENSE OF SECURITY
“So on balance I fear that uptake will be quite a bit lower.”
“Another confounder is that quite a high proportion of the population might have also had a COVID episode in recent months,” said Penny Ward, visiting professor in pharmaceutical medicine at King’s College London.
Some may erroneously feel that having had a complete primary course and then having fallen ill with COVID means they will remain immune, she added.
Since Sept. 5, when the roll-out of new vaccines began in the European Union, about 40 million vaccine doses produced by Pfizer-BioNTech (22UAy.DE) and Moderna (MRNA.O) have been delivered to member states, according to data from the European Centre for Disease Prevention and Control (ECDC).
However, weekly vaccine doses administered in the EU were only between 1 million and 1.4 million during September, compared with 6-10 million per week during the year-earlier period, ECDC data showed.
Perhaps the biggest challenge to uptake is the perception that the pandemic is over, creating a false sense of security.
“There must be some complacency in that life seems to have gone back to normal – at least with regards COVID and people now have other financial and war-related worries,” said Adam Finn, chair of ETAGE, an expert group advising the WHO on vaccine preventable diseases in Europe.
He added that some law-makers, too, were dropping the ball.
Italy’s Gimbe science foundation said the government, soon to be replaced after an election, was ill prepared for the autumn-winter season, and highlighted that a publication on the government’s management of the pandemic had been blocked.
The health ministry declined to comment.
Meanwhile, British officials last week warned that renewed circulation of flu and a resurgence in COVID-19 could pile pressure on the already stretched National Health Service (NHS).
The US Govt. is Pushing New Boosters Amid Low Uptake
The White House is pushing newly released data on the benefits of the COVID-19 vaccinations as uptake for the updated bivalent booster shot remains low one month after it was authorized.
- A new study from the Department of Health and Human Services (HHS), not yet published in a peer-reviewed journal, estimated that coronavirus vaccines were linked to roughly 670,000 to 680,000 fewer hospitalizations as well as 330,000 to 370,000 fewer related deaths from September 2020 to December 2021.
- According to HHS, these estimates represented between 39 and 47 percent fewer deaths than in a possible scenario in which vaccines were not available. The research did not include potential cases that were averted, with HHS citing the rise in at-home testing that isn’t reported to officials.
- On top of these potentially averted deaths and hospitalizations, the HHS study estimated more than $16 billion in direct hospitalization costs were saved due to immunization.
In a press briefing on Friday, Health and Human Services Secretary Xavier Becerra said this research “doubles down on the work that we’re doing on vaccination.”
“We’ve been trying to make sure that we stay ahead of this virus and keep America notonly healthy but strong and keep our economy healthy and strong,” said Becerra.
White House COVID-19 Response Coordinator Ashish Jha said almost every death due to COVID-19 in the U.S. is now preventable, adding that the administration was “laser focused” on reducing illnesses and deaths in the country, though he declined to give an exact numerical goal when asked.
Part of achieving the administration’s goal begins with “making sure that every American gets an updated COVID vaccine,” Jha said.